Therapeutic Asset Ratings

3,848 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
cd1a-car t Acute T-lymphoblastic Leukemia	The Affiliated Hospital of Xuzhou Medical University	P2	B (60)
Chimeric Antigen Receptor Modified T Cells Infusion Acute T-lymphoblastic Leukemia	Shenzhen Geno-Immune Medical Institute	P2	B (60)
Chimeric Antigen Receptor Modified T Cells Infusion Acute T-lymphoblastic Lymphoma	Tianjin Medical University General Hospital	P2	B (60)
Dc-Cik First-line Treatment	Tianjin Medical University Cancer Institute and Hospital	P2	B (60)
dll3-car-nk cells Extensive Stage Lung Small Cell Cancer	Tianjin Medical University Cancer Institute and Hospital	P2	B (60)
e7 tcr-t cells HPV-Associated Cervical Carcinoma	Christian Hinrichs	P2	B (60)
e7 tcr-t cells Oropharynx Cancer	Christian Hinrichs	P2	B (60)
e7 tcr-t cells Penile Cancer	Christian Hinrichs	P2	B (60)
e7 tcr-t cells Vaginal Cancer	Christian Hinrichs	P2	B (60)
e7 tcr-t cells Vulva Cancer	Christian Hinrichs	P2	B (60)
hbi0101 cart Multiple Myeloma, Refractory to Standard Treatment	Hadassah Medical Organization	P2	B (60)
Hpc, Cord Blood Acute Lymphoblastic Leukemia (ALL)	Memorial Sloan Kettering Cancer Center	P2	B (60)
Kyv-101 Multiple Sclerosis, Primary Progressive	Kyverna Therapeutics	P2	B (60)
Kyv-101 Multiple Sclerosis, Secondary Progressive	Kyverna Therapeutics	P2	B (60)
Pcar-19B Cells Relapsed Pediatric ALL	Chongqing Precision Biotech Co., Ltd	P2	B (60)
TIL Locally Advanced Melanoma	City of Hope Medical Center	P2	B (60)
Tisagenlecleucel B-Cell CLL	National Cancer Institute (NCI)	P2	B (60)
Treg Cells Chronic Myelogenous Leukemia	Masonic Cancer Center, University of Minnesota	P2	B (60)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Myelodysplastic Syndrome	Fred Hutchinson Cancer Center	P2/3	B (60)
cd19-ucart T Cell Lymphoma	Beijing GoBroad Hospital	P1/2	B (60)
Rondecabtagene Autoleucel Large B-cell Lymphoma	Lyell Immunopharma, Inc.	P3	B (59)
Tisagenlecleucel Follicular Lymphoma	Novartis Pharmaceuticals	P3	B (59)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Acute Myelocytic Leukemia	Anhui Provincial Hospital	P2	B (59)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Non-Hodgkin Lymphoma	David Wald	P2	B (59)
Chimeric Antigen Receptor Modified T Cells Infusion Lymphoma, B-Cell	Shanxi Bethune Hospital	P2	B (59)

Showing 101 to 125 of 3,848 assets

PreviousPage 5 of 154Next